FOLFIRI-3 after FOLFOX for colorectal cancer
Author Information
Author(s): Mabro M, Artru P, André T, Flesch M, Maindrault-Goebel F, Landi B, Lledo G, Plantade A, Louvet C, de Gramont A
Primary Institution: Hôpital Foch
Hypothesis
The study aimed to establish the efficacy and safety of the FOLFIRI-3 regimen in advanced colorectal cancer patients previously treated with FOLFOX.
Conclusion
FOLFIRI-3 is a promising regimen achieving a high response rate and progression-free survival in patients previously treated with FOLFOX with moderate toxicity.
Supporting Evidence
- The intent-to-treat objective response rate was 23%.
- Median progression-free survival was 4.7 months.
- Median survival was 10.5 months.
- Main toxicities included grade 3–4 diarrhoea in 23% of patients.
Takeaway
This study tested a new treatment for colorectal cancer that had not worked well with previous treatments, and it showed that the new treatment could help some patients feel better.
Methodology
This was an open multicentre phase II study where patients received the FOLFIRI-3 regimen every 14 days, and their responses were monitored.
Limitations
The study had a relatively small sample size and was limited to patients previously treated with FOLFOX.
Participant Demographics
{"median_age":60,"gender_distribution":{"male":32,"female":33},"performance_status":{"0":32,"1":22,"2":11}}
Statistical Information
Confidence Interval
95% CI 13–33%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website